|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Additional conditions recognized in this trial | ||||
| Fever | |||||
| Hemorrhagic Fever with Renal Syndrome | |||||
| Hemorrhagic Fevers, Viral | |||||
| Syndrome | |||||
| 2 | More general conditions related to this trial | ||||
| Body Temperature Changes | |||||
| Bunyaviridae Infections | |||||
| Disease | |||||
| Hantavirus Infections | |||||
| Pathologic Processes | |||||
| RNA Virus Infections | |||||
| Signs and Symptoms | |||||
| Virus Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| Ribavirin | |||||
| 4 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antimetabolites | |||||
| Antiviral Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| U.S. Army Medical Research and Materiel Command | |||||